NSC 286193

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1982-2006
02419822006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
A phase I trial of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NCS 286193, tiazofurin) was conducted using a 5-day i.v. bolus… (More)
Is this relevant?
1990
1990
The authors studied the metastasis-inhibiting effect of various dosages of tiazofurin in mice inoculated with a low (LLT) and a… (More)
Is this relevant?
1989
1989
Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193), a selective inhibitor of the activity of IMP dehydrogenase… (More)
  • figure I
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1987
1987
A patient with refractory acute myeloid leukemia was treated with tiazofurin, an agent that causes inhibition of tumor cell… (More)
  • figure 1
Is this relevant?
1986
1986
A phase I and pharmacokinetic study of tiazofurin (NSC 286193), a C-nucleoside that inhibits IMP dehydrogenase, has been… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1985
1985
Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, TCAR, Riboxamide, NSC 286193) is a novel C-nucleoside with antitumor… (More)
Is this relevant?
1985
1985
A Phase I trial of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193, tiazofurin) was conducted using a 5-day continuous… (More)
Is this relevant?
1985
1985
Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), a new nucleoside antimetabolite, was evaluated in a phase I trial… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
1985
1985
Tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, TCAR) is a synthetic C-nucleoside that demonstrated significant in vivo… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1982
1982
Administration of the novel thiazole C-nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193), to BDF1 mice… (More)
Is this relevant?